TRIB · Trinity Biotech PLC · Metrics
$5.70
-0.20 (-3.31%)
At close · Nov 6
Return incl. dividend (before tax)
Q3 2024 earnings call transcript
Market Cap
$4.63M
Shares
813,132
Volume · Nov 6
8827
Avg daily vol (3M)
19.13K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
TRIB metrics
42 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$5.70
Market cap
$4.63M
Price action
23 metricsPrice change (1W)
-11.1%
Price change (30D)
-12.7%
Price change (3M)
-49.4%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
120.9%
Annualized volatility (3M)
101.8%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
37.4
Price vs SMA 50
-20.3%
Price vs SMA 200
—
Avg volume (3M)
19,166
Relative volume
0.7
Average dollar volume
$180,249
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
813,132
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-761.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-09-30
Profitability
9 metricsGross margin
38.6%
Operating margin
-36.1%
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
−$36.48M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-1.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-1.5%
Shares change YoY
+4.2%
Year over year · more shares
Revenue CAGR (3Y)
-11.2%
Revenue CAGR (5Y)
-15.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-36.6%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.14M
Total assets
$105.17M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
20
13F filer change QoQ
-5
Institutional ownership
4.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-7.6%
Holder tenure
19.6
Price vs estimated holder cost
-70.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.1%
Short interest
3 metricsShort interest
3.9%
Latest settlement · 1.7 days to cover
Days to cover
1.7d
Short-squeeze score
59 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—